Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Identifying biomarkers of the resistance in multiple myeloma (MM) is a key research challenge. We aimed to identify proteins that differentiate plasma cells in patients with refractory/relapsed MM (RRMM) who achieved at least very good partial response (VGPR) and in those with reduced response to PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Dytfeld, Dominik, Luczak, Magdalena, Wrobel, Tomasz, Usnarska-Zubkiewicz, Lidia, Brzezniakiewicz, Katarzyna, Jamroziak, Krzysztof, Giannopoulos, Krzysztof, Przybylowicz-Chalecka, Anna, Ratajczak, Blazej, Czerwinska-Rybak, Joanna, Nowicki, Adam, Joks, Monika, Czechowska, Elzbieta, Zawartko, Magdalena, Szczepaniak, Tomasz, Grzasko, Norbert, Morawska, Marta, Bochenek, Maciej, Kubicki, Tadeusz, Morawska, Michalina, Tusznio, Katarzyna, Jakubowiak, Andrzej, Komarnicki, Mieczysław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302948/
https://www.ncbi.nlm.nih.gov/pubmed/27527861
http://dx.doi.org/10.18632/oncotarget.11059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302948/
https://www.ncbi.nlm.nih.gov/pubmed/27527861
http://dx.doi.org/10.18632/oncotarget.11059

Ejemplares similares